PULMONX CORPORATION Revenue
PULMONX CORPORATION (LUNG) reported Revenue of $22.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $22.76M, a 4.62% decline year-over-year.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $20.59M, a 8.66% decline year-over-year.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $22.60M, a 4.91% decline year-over-year.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $21.50M, a 5.47% increase year-over-year.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $90.50M, a 8.01% increase from fiscal 2024.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $83.79M, a 22.01% increase from fiscal 2023.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $68.67M, a 27.98% increase from fiscal 2022.
- PULMONX CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $53.66M, a 10.84% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.76M 10-Q · filed 2026-08-04 | $43.34M 10-Q · filed 2026-08-04 | $65.94M derived: sum of 3 quarters · filed 2026-08-04 | $87.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $20.59M 10-Q · filed 2026-05-04 | $43.18M derived: sum of 2 quarters · filed 2026-05-04 | $64.69M derived: sum of 3 quarters · filed 2026-05-04 | $88.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $22.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $44.10M derived: sum of 2 quarters · filed 2026-03-10 | $67.96M derived: sum of 3 quarters · filed 2026-08-04 | $90.50M 10-K · filed 2026-03-10 |
| 2025-09-30 | $21.50M 10-Q · filed 2025-11-12 | $45.36M derived: sum of 2 quarters · filed 2026-08-04 | $67.90M 10-Q · filed 2025-11-12 | $91.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $23.86M 10-Q · filed 2026-08-04 | $46.40M 10-Q · filed 2026-08-04 | $70.16M derived: sum of 3 quarters · filed 2026-08-04 | $90.55M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $22.54M 10-Q · filed 2026-05-04 | $46.30M derived: sum of 2 quarters · filed 2026-05-04 | $66.69M derived: sum of 3 quarters · filed 2026-05-04 | $87.47M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $23.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $44.15M derived: sum of 2 quarters · filed 2026-03-10 | $64.94M derived: sum of 3 quarters · filed 2026-03-10 | $83.79M 10-K · filed 2026-03-10 |
| 2024-09-30 | $20.39M 10-Q · filed 2025-11-12 | $41.17M derived: sum of 2 quarters · filed 2025-11-12 | $60.02M 10-Q · filed 2025-11-12 | $79.30M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $20.78M 10-Q · filed 2025-08-01 | $39.64M 10-Q · filed 2025-08-01 | $58.91M derived: sum of 3 quarters · filed 2025-08-01 | $76.58M derived: sum of 4 quarters · filed 2025-08-01 |
| 2024-03-31 | $18.85M 10-Q · filed 2025-05-02 | $38.13M derived: sum of 2 quarters · filed 2025-05-02 | $55.80M derived: sum of 3 quarters · filed 2025-05-02 | $72.99M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $19.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $36.95M derived: sum of 2 quarters · filed 2025-02-25 | $54.14M derived: sum of 3 quarters · filed 2025-02-25 | $68.67M 10-K · filed 2025-02-25 |
| 2023-09-30 | $17.67M 10-Q · filed 2024-11-01 | $34.86M derived: sum of 2 quarters · filed 2024-11-01 | $49.40M 10-Q · filed 2024-11-01 | $64.82M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $17.19M 10-Q · filed 2024-08-02 | $31.73M 10-Q · filed 2024-08-02 | $47.15M derived: sum of 3 quarters · filed 2024-08-02 | $60.66M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $14.54M 10-Q · filed 2024-05-03 | $29.96M derived: sum of 2 quarters · filed 2024-05-03 | $43.46M derived: sum of 3 quarters · filed 2024-05-03 | $57.41M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $28.93M derived: sum of 2 quarters · filed 2024-02-27 | $42.88M derived: sum of 3 quarters · filed 2024-02-27 | $53.66M 10-K · filed 2024-02-27 |
| 2022-09-30 | $13.50M 10-Q · filed 2023-11-03 | $27.45M derived: sum of 2 quarters · filed 2023-11-03 | $38.24M 10-Q · filed 2023-11-03 | $51.95M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $13.95M 10-Q · filed 2023-08-04 | $24.73M 10-Q · filed 2023-08-04 | $38.44M derived: sum of 3 quarters · filed 2023-08-04 | $51.70M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $10.79M 10-Q · filed 2023-05-08 | $24.49M derived: sum of 2 quarters · filed 2023-05-08 | $37.75M derived: sum of 3 quarters · filed 2023-05-08 | $49.96M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $13.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $26.97M derived: sum of 2 quarters · filed 2023-03-01 | $39.17M derived: sum of 3 quarters · filed 2023-03-01 | $48.42M 10-K · filed 2023-03-01 |
| 2021-09-30 | $13.26M 10-Q · filed 2022-11-08 | $25.46M derived: sum of 2 quarters · filed 2022-11-08 | $34.71M 10-Q · filed 2022-11-08 | $44.54M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $12.20M 10-Q · filed 2022-08-08 | $21.45M 10-Q · filed 2022-08-08 | $31.28M derived: sum of 3 quarters · filed 2022-08-08 | $41.89M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $9.24M 10-Q · filed 2022-05-09 | $19.07M derived: sum of 2 quarters · filed 2022-05-09 | $29.69M derived: sum of 3 quarters · filed 2022-05-09 | $33.36M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $9.83M 10-K · filed 2021-03-15 | $20.44M derived: sum of 2 quarters · filed 2021-11-09 | $24.11M derived: sum of 3 quarters · filed 2021-11-09 | $32.73M 10-K · filed 2022-03-01 |
| 2020-09-30 | $10.61M 10-Q · filed 2021-11-09 | $14.29M derived: sum of 2 quarters · filed 2021-11-09 | $22.90M 10-Q · filed 2021-11-09 | $33.25M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.67M 10-Q · filed 2021-08-10 | $12.29M 10-Q · filed 2021-08-10 | $22.64M derived: sum of 3 quarters · filed 2021-08-10 | $31.74M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $8.62M 10-Q · filed 2021-05-12 | $18.96M derived: sum of 2 quarters · filed 2021-05-12 | $28.07M derived: sum of 3 quarters · filed 2021-05-12 | $35.44M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $10.35M 10-K · filed 2021-03-15 | $19.45M derived: sum of 2 quarters · filed 2021-03-15 | $26.82M derived: sum of 3 quarters · filed 2021-03-15 | $32.59M 10-K · filed 2021-03-15 |
| 2019-09-30 | $9.10M 10-K · filed 2021-03-15 | $16.47M derived: sum of 2 quarters · filed 2021-03-15 | $22.25M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $7.37M 10-K · filed 2021-03-15 | $13.14M derived: sum of 2 quarters · filed 2021-03-15 | ||
| 2019-03-31 | $5.78M 10-K · filed 2021-03-15 | |||
| 2018-12-31 | $20.00M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |